Investments
9Portfolio Exits
2About jVen Capital
jVEN Capital, LLC is a venture capital and investment management company focused on the Life Sciences. The company is active in the areas of personalized medicine, genetics, medical devices, and specialty therapeutics. The firm was established in 2007 by Evan Jones, an entrepreneur in the molecular diagnostics field. Current investments include OpGen Inc., Signature Genomic Laboratories, LLC, Veracyte Inc, and CAS Medical Systems Inc.
Latest jVen Capital News
Aug 25, 2023
Kyverna Therapeutics – a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases – recently announced the closing of an oversubscribed $60 million Series B financing round extension, bringing the total Series B financing round to $145 million. New investors Bain Capital Life Sciences and GordonMD Global Investments LP join existing investors Gilead Sciences, Westlake Village BioPartners, Vida Ventures, Northpond Ventures, RTW Investments, Insight Partners, CAM Capital, LYFE Capital, jVen Capital, and others. Chimeric antigen receptor (CAR) T-cell therapy involves modifying a patient’s immune T cells to recognize and remove B cells in the patient’s body. And Kyverna’s anti-CD19 CAR T-cell therapies, KYV-101 and KYV-201, specifically target CD19, a protein expressed on the surface of B cells involved in various types of autoimmune diseases, including lupus nephritis. These novel therapies have the potential to offer new hope to patients who have exhausted current treatment options. And Kyverna continues to explore additional indications for its anti-CD19 CAR T-cell therapies and develop a solid pipeline of promising immunotherapies to address unmet medical needs. KEY QUOTES: “We are pleased by the increasing investor confidence in the promise of Kyverna’s anti-CD19 CAR T-cell therapy for autoimmune diseases. This Series B extension will fund Kyverna’s clinical studies in the U.S. and Europe, enabling us to move more quickly toward bringing potentially transformative and life-saving therapies to patients. We continue to treat autoimmune patients in multiple indications and multiple geographies, and we look forward to sharing clinical data in the second half of 2023.” — Ryan Jones, chief financial officer of Kyverna “I have supported anti-CD19 CAR T-cell therapy for cancer since the early clinical trials. It is exciting to see Kyverna break into new frontiers by advancing cell therapies for autoimmune diseases. I am looking forward to future developments from Kyverna.” — Craig Gordon, M.D., founder, chief executive officer, and chief investment officer of Gordon MD Global Investments LP Trending on Pulse 2.0
jVen Capital Investments
9 Investments
jVen Capital has made 9 investments. Their latest investment was in Kyverna Therapeutics as part of their Series B - II on August 8, 2023.

jVen Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
8/3/2023 | Series B - II | Kyverna Therapeutics | $60M | No | 3 | |
1/26/2022 | Series B | |||||
12/23/2014 | Series D - II | |||||
5/21/2014 | Series D | |||||
5/21/2012 | Series C |
Date | 8/3/2023 | 1/26/2022 | 12/23/2014 | 5/21/2014 | 5/21/2012 |
---|---|---|---|---|---|
Round | Series B - II | Series B | Series D - II | Series D | Series C |
Company | Kyverna Therapeutics | ||||
Amount | $60M | ||||
New? | No | ||||
Co-Investors | |||||
Sources | 3 |
jVen Capital Portfolio Exits
2 Portfolio Exits
jVen Capital has 2 portfolio exits. Their latest portfolio exit was Assurex Health on August 04, 2016.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
8/4/2016 | Acquired | 1 | |||
Date | 8/4/2016 | |
---|---|---|
Exit | Acquired | |
Companies | ||
Valuation | ||
Acquirer | ||
Sources | 1 |
Loading...